NEW YORK, May 3, 2023 /PRNewswire/ — The Gross Law Firm issues the following notice to shareholders of Relmada Therapeutics, Inc.: Before market opened on October 13, 2022, Relmada announced the results of its RELIANCE III study (REL-1017-303), evaluating the drug REL-1017 as a…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.